Drug Trial Radar · NCT07122414
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 16, 2024
Primary completion
Oct 10, 2027
Study completion Oct 10, 2028
Sponsor
- Lead sponsor
- Suzhou Forlong Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the safety and tolerability of intravesical FL115 alone or in combination with BCG in the patients with NMIBC, and to determine the RP2D of FL115 in combination with BCG. To evaluate the preliminary efficacy of FL115 alone or in combination with BCG in the treatment of NMIBC. The study consists of three parts: FL115 monotherapy dose escalation (Phase Ia), FL115 combined with BCG dose escalation (Phase Ib), and FL115 combined with BCG cohort expansion (Phase II). Each subject will receive FL115 alone or in combination with intravesical BCG, administered over three treatment periods: induction, enhanced induction/maintenance 1, and maintenance 2.
Conditions
- Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
FL115Drug
FL115 single agent dose escalation,
FL115+BCGDrug
FL115 in combination with BCG
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: up to 15 months
- RP2DTime frame: up to 15 months
- Safety and tolerabilityTime frame: through study completion, up to 5 years
- Complete ResponseTime frame: 36 months
- Disease-Free RateTime frame: 12 months
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Cancer Hospital
Shanghai, China · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Fujian, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
The Second Hospital of Tianjin Medical University
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.